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Abstract 
The synthetic tryptamine 5-methoxy-N-methyl-N-isopropyltryptamine (5-MeO-MiPT) has recently 
been abused as a hallucinogenic drug in Germany and Switzerland. This study presents a case of 5-
MeO-MiPT intoxication and the structural elucidation of metabolites in pooled human liver 
microsomes (pHLM), blood, and urine. Microsomal incubation experiments were performed using 
pHLM to detect and identify in vitro metabolites. In August 2016, the police encountered a naked 
man, agitated and with aggressive behavior on the street. Blood and urine samples were taken at 
the hospital and his premises was searched. The obtained blood and urine samples were analyzed 
for in vivo metabolites of 5-MeO-MiPT using LC-high resolution MS/MS (LC-HR-MS/MS). The 
confiscated pills and powder samples were qualitatively analyzed using FTIR, GC-MS, LC-HR-MS/MS 
and NMR. 5-MeO-MiPT was identified in two of the seized powder samples. General unknown 
screening detected cocaine, cocaethylene, methylphenidate, ritalinic acid and 5-MeO-MiPT in urine. 
Seven different in vitro phase I metabolites of 5-MeO-MiPT were identified. In the forensic case 
samples, four phase I metabolites could be identified in blood and seven in urine. The five most 
abundant metabolites were formed by demethylation and hydroxylation of the parent compound. 5-
MeO-MiPT concentrations in the blood and urine sample were found to be 160 ng/mL and 3380 
ng/mL, respectively. Based on the results of this study we recommend metabolites 5-methoxy-N-
isopropyltryptamine (5-MeO-NiPT), 5-hydroxy-N-methyl-N-isopropyltryptamine (5-OH-MiPT), 5-
methoxy-N-methyl-N-isopropyltryptamine-N-oxide (5-MeO-MiPT-N-oxide) and hydroxy-5-methoxy-
N-methyl-N-isopropyltryptamine (OH-5-MeO-MiPT) as biomarkers for the development of new 
methods for the detection of 5-MeO-MiPT consumption, as they have been present in both blood 
and urine samples.  
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Introduction 
Since their first occurrence as recreational drugs, new psychoactive substances (NPS) have taken 
over the online drug market. The initial appeal of NPS was that these substances were legally and 
easily available via the internet[1, 2] and were untraceable by commonly used immunoassay drug 
tests[3, 4]. The European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) is monitoring 
over 620 substances[5], classified into different chemical classes including phenethylamines, 
cathinone derivatives, synthetic cannabinoids, piperazines and tryptamines [6]. In this last category, 
16 tryptamines have been recorded since 2009[7].  
 
The NPS market is constantly changing with alone 101, 98 and 66 new substances emerging in 2014, 
2015 and 2016, respectively [5, 7]. As soon as a substance is legally controlled its structure is altered in 
order to evade legislations once again[2, 8, 9]. These structural alterations can result in a modified 
pharmacological and toxicological profile [10]. When new substances appear on the market, only little 
is usually known about their mode of action, metabolism and toxicity, making the assessment of 
potential harms in humans challenging.  
NPS were initially derived from pharmaceutical research. An example of a tryptamine researched 
and developed for pharmaceutical application is alpha-methyltryptamine (AMT). It was developed in 
the 1960s as an antidepressant in the Soviet Union and was studied for its clinical value by the 
Upjohn Pharmaceutical Company. Although it was shown to have no therapeutically applicability 
AMT became popular in the 1990s as an NPS because of its purported hallucinogenic properties [9, 11]. 
Tryptamines are originally derived from natural sources such as toads, plants, mushrooms [12], 
microbes and amphibians [13]. Naturally occurring tryptamines with a classical psychedelic profile are 
for example N,N-dimethyltryptamine (DMT), 4-phorphoryloxy-N,N-dimethyltryptamine (psilocybin) 
and 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) [14]. First synthetic analogs of tryptamines 
have become sold on the designer drug market in the late 1990s [14] and have become recently 
available and more popular on the internet [9]. These derivatives are structurally related to the 
neurotransmitter serotonin (5-hydroxytryptamine, 5-HT) [12]. Serotonin is one of the most important 
signaling hormones in the body [15] and is involved in the regulation of a variety of functions such as 
appetite, sex, sleep, cognition and memory, sensory perception, mood, nociception, endocrine 
function, temperature regulation, motor activity and behavior [16]. It is today’s understanding that 
the hallucinogenic properties of tryptamines lie in the principal structural feature of the tryptamine 
nucleus [17] and additionally is greatly affected by substitution on the indole ring, the side-chain 
carbons and alkylation of the side-chain nitrogen [18]. Moreover, the psychoactive effects of 
hallucinogens are modulated mainly via the 5-HT2A  
[12, 19, 20] and 5-HT1A receptor 
[14], with possible 
additional receptor subtypes being important, which has been shown in an extensive study with 35 
psychoactive tryptamine analogs being evaluated for their binding profiles [21]. One of the most 
common routes of synthesis has been adapted from the method of Speeter and Anthony [17, 22]. For 
this approach, an indole precursor is acylated with oxalyl chloride followed by the formation of 3-
ylglyoxalylamide. Finally reduction with lithium aluminum hydride produces the desired tryptamine 
compound [22, 23]. Research on synthetic tryptamines has been published by Alexander Shulgin and 
Ann Shulgin and has been described in the book TiHKAL [24]. 
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The psychedelic and hallucinogenic drug 5-methoxy-N-methyl-N-isopropyltryptamine (5-MeO-MiPT) 
is chemically related to the naturally occurring tryptamine 5-MeO-DMT and is an analogue of the 
synthetic tryptamine 5-methoxy-N,N-diisopropyltryptamine (5-MeO-DiPT), also known as Foxy or 
Foxy methoxy. Therefore, 5-MeO-MiPT is often also referred to as Moxy [13]. 5-MeO-DiPT was placed 
in Schedule I of the Controlled Substances Act in the United States in 2004 [25]. Studies have 
suggested that 5-MeO-DiPT has potent neurotoxic effects on the serotonergic neurons [26] which is 
consistent with behavioral data [27]. It has been clinically shown to promote emotional expression, a 
talkative uninhibited state and visual and auditory sensory distortion [24, 28, 29].  
The synthesis and psychoactive effects of 5-MeO-MiPT were first described by Repke et. al [30]. 
Alexander Shulgin and Ann Shulgin recommend doses of 4-6 mg for oral consumption and higher 
doses of 12-20 mg for administration via smoking[24]. The attachment of a 5-methoxy group to the 
tryptamine core has been found to increase potency [9] and to decrease the effects on perceptual 
changes in vision [30]. N-Substitutions have also been reported to have an influence on the in vivo 
potency of tryptamines [30, 31]. It has been demonstrated that 5-MeO-MiPT inhibits the re-uptake of 
5-HT, dopamine and norepinephrine, a mechanism of action similar to that of 5-MeO-DiPT. 
Furthermore, it was shown to have little dopamine, 5-HT and norepinephrine releasing activity [13, 32]. 
In Switzerland 5-MeO-MiPT is listed in the “Federal Act on Narcotics and Psychotropic Substances” 
index e, No. 85 [33]. Until now, however, it has not been listed in the neighboring state Germany [34]. 
Metabolism studies are a valuable tool in forensic science. Data obtained from these studies help to 
decide on biomarkers not only as target for the development of new bioanalytical methods [35], but 
also to prove consumption of a drug of abuse. 
For the study of NPS metabolism different in vivo and in vitro models can be used for the formation 
of phase I and phase II metabolites. In vivo experiments involving human subjects are difficult to 
conduct, due to obvious health risks and ethical questions. Mice, rats and primates can be used as 
alternative in vivo models. However, these also suffer from limitations such as ethical constraints, 
high costs, time, and species difference to humans [36]. In vitro experiments, such as pooled human 
liver microsomes (pHLM), hepatocytes or perfused liver are adequate alternatives. The pHLM model 
has been widely used for metabolism studies of different substance classes of NPS [37-39], including 
synthetic tryptamines [40]. Although pHLM assays do not always produce a metabolite pattern 
completely congruent with the one observed in human urine and blood, they are still a valuable tool 
in metabolism studies.  
So far, publications available on 5-MeO-MiPT have focused on receptor interaction profiles [12], 
receptor functional data [41], effects on monoamine neurotransmission in rat brain [42], 
characterization of the synthetic route [18] and the simultaneous detection of 31 NPS [43]. Studies on 
the receptor interaction profiles by Rickli et al. [12] could show that 5-MeO-MiPT is a near-full (83 %) 
agonist at the 5-HT2A receptor but had no relevant action at the human monoamine transporters. A 
case study described the intoxication with 78 mg of 5-MeO-MiPT in combination with 120 mg of 
methylone which led to adverse effects and hospitalization of the man [44]. Shima et al. [45] reported 
on the detection of three in vivo metabolites in two different individuals, one of them being fatal. 
However, they gave no description of the experimental procedure and how the metabolites were 
identified. Recently Fabregat-Safont et al. [46] identified four 5-MeO-MiPT metabolites in total in 
serum and urine samples of adult male C57BLJ/6 mice.  
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This paper presents a detailed analysis of phase I in vitro metabolites of 5-MeO-MiPT, using pHLM 
and phase I and phase II in vivo metabolites found in authentic blood and urine samples after 5-
MeO-MiPT intoxication. Identification of drugs and metabolites was performed by LC-high resolution 
MS/MS (LC-HR-MS/MS), quantification of 5-MeO-MiPT in the case samples were performed using 
LC-MS/MS and chemical analyses of seized material were performed using FTIR, GC-MS, LC-HR-
MS/MS and NMR.  
Case report 
In late August 2016 the police was called by a friend of a man, who supposedly had taken a “LSD-like 
substance”. The police encountered a 32 year old male (height 184 cm, weight 84 kg) standing naked 
and without orientation on the street. He had several abrasions all over his body and seemed to be 
in conation (a “bad state”). When approached by the police, the suspect reacted agitated and 
aggressive. The man was then handcuffed and taken to the hospital. A blood sample was collected 
one hour and a urine sample two hours after the police appeared at the scene. The second man 
present at the scene was tested positive for THC and opiates using a lateral flow immuno-test. Both 
men´s flats were searched and one sachet containing eight yellow candy-like pills (sample 1) and 
three different powder sachets (sample 2-4) were confiscated. Blood and urine samples of the first 
suspect and all seized material were sent to the Institute of Forensic Medicine Bern for analysis.  
Materials and Methods 
Chemicals and Reagents 
Sulfosalicylic acid and superoxide dismutase (6016 units/mg protein) were obtained from Sigma 
Aldrich (Buchs, Switzerland), sodium hydroxide and magnesium chloride from Merck AG (Zug, 
Switzerland). The following reference standards were obtained from Cerilliant (Round Rock, TX, 
USA): ecgonine methyl ester-D3 (0.1 mg/mL in MeOH), tramadol-d3C13 (0.1 mg/mL in MeOH), THC-D3 
(0.1 mg/mL in MeOH) and MBDB-D5 (0.01 mg/mL in MeOH). The reference standards D,L-
amphetamine (HCl, >98.5 %), D,L-methamphetamine (HCl, 98.5 %), D,L-MDMA (HCl, >98.5 %), and 
3,6-diacetylmorphine were purchased from Lipomed (Arlesheim, Switzerland), and cocaine-HCl (>99 
%) from Siegfried AG (Zolfingen, Switzerland). Methanol (absolute, HPLC grade) was purchased from 
Biosolve (Chemie Brunschwig, Basel, Switzerland), acetonitrile (HPLC gradient grade, 99.9 %) from 
Acros Organics (Chemie Brunschwig, Basel, Switzerland), formic acid (analytical grade, 98 %) and 
ammonium formate from Fluka (Sigma-Aldrich, Buchs, Switzerland). Deuterated chloroform (CDCl3) 
was obtained from Cambridge Isotopes Laboratories (Tewksbury, MA, USA). Ultrapure water was 
produced in-house with a Direct-Q water purification system from Millipore (Zug, Switzerland). Blank 
blood and urine were provided by healthy volunteers and were tested with the presented LC-HR-
MS/MS method to ensure the absence of drugs of abuse. Urine samples were collected in plastic 
containers without adding a preservative. Pooled human liver microsomes (pHLM) (150 donors, 
20mg/mL), NADPH-regenerating solutions A/B and 0.5 M potassium phosphate buffer pH 7.4 were 
purchased from Corning (New York, NY, USA). Precision pipettes from Gilson (Mettmenstetten, 
Switzerland) and Socorex Isba S.A (Ecublens, Switzerland) were used for handling of all solutions and 
samples. A reference standard of 5-MeO-MiPT·HCl (>98 %) was kindly provided by the Forensic 
Institute Zurich, Switzerland and used for pHLM experiments.  
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In Silico predictions 
To assist in the interpretation of the collected mass spectrometric data, in silico predictions were 
performed using EAWAG-BBD Pathway Prediction System (formerly known as UM-BBD/PPS) [47-49]. It 
predicts plausible pathways for aerobic microbial degradation of chemical compounds using 
biotransformation rules, based on reactions found in the EAWAG-BBD database and in the scientific 
literature. This includes a multi-level prediction with testing query compounds against rules, 
validating product qualifications and displaying all qualified products in one or more plausible 
pathway branches. It differentiates the likelihood of predicted degradation products based on their 
aerobic likelihood into very likely (dark green), likely (light green) or neutral (yellow) (for the 
generated predictions of 5-MeO-MiPT see Supporting Information Figure S1) [50]. A recursive 
prediction method is used to construct the pathway. It starts from the initial query compound, which 
is inserted as a SMILES string, followed by further prediction levels until the breadth (row) or depth 
(levels) reaches chosen cut-off values. Default values, which have been applied, are ten compounds 
in breadth and six in depth. Once the prediction is completed, an automatic layout algorithm is 
applied and the graphical pathway is produced by the GraphViz dot program [49]. Predicted 
degradation products are then compared to full scan LC-HR-MS/MS measurements using Analyst 
software 1.6 TF with the extracted ion current (XIC) tool.  
In vitro metabolism assay for pHLM incubations and sample preparation for screening 
Microsomal in vitro experiments were performed to generate phase I metabolites. The final reaction 
volume was 50 µL. Potassium phosphate buffer (100 mM), deionized water, NADPH-regenerating 
solution A (NADP+ and glucose-6-phosphate) and B (glucose-6-phosphate dehydrogenase), 
magnesium chloride (5mM), superoxide dismutase (200 units/mL), pHLM (1 mg/mL) and a reference 
standard of 5-MeO-MiPT (100 mM), were mixed in a reaction tube and incubated for 120 minutes at 
37 °C (indicated concentrations are final concentrations). Blanks containing no drug substrate and 
negative controls containing no pHLM were processed accordingly. Reactions were stopped by the 
addition of extraction solvents. Experiments were repeated at least 6 times for every MS 
experiment. 
Two different extraction procedures were used in order to take into account potential differences in 
the extraction behavior of the metabolites. The first procedure consisted of protein precipitation by 
adding 50 µL ice-cold acetonitrile. The sample was then centrifuged at 17,000 g and 4 °C for 10 
minutes. The supernatant was transferred into an autosampler vial, evaporated to dryness at 50 °C 
under nitrogen and reconstituted in 50 µL of water/acetonitrile/formic acid, (95:5:0.1; v/v/v). The 
second procedure involved liquid-liquid extraction with 20 % sulfosalicylic acid, acetonitrile and 
ammonium formate (10 mM) (7:80:13, v/v/v) followed by centrifugation at 17,000 g for ten minutes 
at 4 °C. The organic phase was transferred into an autosampler vial containing ethylene glycol (5 µL), 
which was added to avoid evaporation of compounds and further to avoid compounds being 
attached to the walls of the vial and hence not be reconstituted. Finally the organic phase was 
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Preparation of authentic blood sample for general unknown screening using LC-HR-MS/MS 
Ten µL of internal standard (ISTD) solution was added to 200 µL of whole blood sample. Protein 
precipitation was performed by adding acetonitrile in a ratio of 1:3. The sample was then 
centrifuged at 17,000 g at 4 °C for 10 minutes and the supernatant was evaporated to dryness under 
nitrogen at 50 °C. The sample was then reconstituted in 200 µL water, acetonitrile, formic acid, 
(97.5/2.5/0.1; v/v/v) with 2.5 mM ammonium acetate and 2.5 mM ammonium formate.  
Preparation of authentic urine sample for general unknown screening using LC-HR-MS/MS 
For the preparation of the urine sample our general in-house urine work-up procedure for LC-HR-
MS/MS was performed as follows: The urine sample (30 µL) was diluted with 10 µL ISTD solution 
containing ecgonine methylester-D3 (500 ng/mL), tramadol-D3
13C1 (500 ng/mL) and THC-D3 (5000 
ng/mL) and 200 µL mobile phase of deionized water, acetonitrile, formic acid (97.5:2.5:0.1; v/v/v) 
with 2.5 mM ammonium acetate and 2.5 mM ammonium formate. The sample was then ready for 
LC-HR-MS/MS analysis.  
 
Preparation of calibration and quality control samples for the quantification of 5-MeO-MiPT 
Working solutions were prepared via dilution of the reference standard solutions in methanol (0.37 
mg/mL) and used for preparing calibration and quality control (QC) samples. Calibration and QC 
working solutions were prepared using separate dilution series and stored at –20 °C in 
polypropylene tubes. Spiking 190 µL blank blood or blank urine with 10 µL of working solution, 
created calibration samples with concentrations of 5, 10, 25, 50, 100, 250, 500 ng/mL and QC 
samples with concentrations of 5, 15, 125 and 400 ng/mL. Linear least-squares regression with a 
weighting factor of 1/x was used for fitting the calibration curve.  
Preparation for the quantification of 5-MeO-MiPT in blood 
Protein precipitation of 200 µL calibration, QC and authentic whole blood samples spiked with 10 µL 
ISTD containing MBMB-D5 (4000 ng/mL), was performed by adding acetonitrile in a ratio of 1:3 (v/v). 
After centrifugation of the samples at 17,000 g at 4 °C for 10 minutes, the supernatant was 
evaporated to dryness under nitrogen at 50 °C. Samples were reconstituted in 200 µL water, 
acetonitrile and formic acid (97.5/2.5/0.1; v/v/v).  
Preparation for the quantification of 5-MeO-MiPT in urine 
Sample preparation of calibration, QC and the authentic urine samples was performed by dilution. A 
30 µL sample was diluted with 10 µL ISTD containing MBMB-D5 (4000 ng/mL) and 200 µL mobile 
phase consisting of deionized water, acetonitrile and formic acid (97.5:2.5:0.1; v/v/v). The sample 
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LC-HR-MS/MS analysis of pHLM, blood and urine samples for phase I and phase II metabolites 
The LC-HR-MS/MS system used for the analysis of pHLM samples, blood, urine and seized samples 
consisted of a Dionex Ultimate 3200 HPLC system (Thermo Fisher Scientific, Reinach, Switzerland) 
coupled to a 5600 TripleTof System equipped with a DuoSpray interface and Analyst software 1.6 TF 
with MasterViewTM Software Version 1.1 (Sciex, Toronto, Canada). MS data was acquired in positive 
ionization mode with an ionspray voltage of 5.0 kV and a source temperature of 650 °C. The curtain 
gas was set to 35 arbitrary units, gas 1 and 2 to 40 arbitrary units. Information dependent  data 
acquisition (IDA) was performed with a survey scan from 100 to 950 m/z, triggering the acquisition 
of product ion mass spectra at a mass range from 50 to 950 m/z. Accumulation time was set to 40 
ms and 50 ms for dependent and survey scans, respectively. Fragmentation was selected for the 
nine most abundant precursor ions with a collision energy of 35 eV and a collision engergy spread of 
± 15 eV.  
The analysis of pHLM samples was performed with the following chromatographic conditions: 
chromatographic separation was performed on a reversed phase Kinetex C8 column, 2.6 µm, 100 Å, 
100 x 2.1 mm (Phenomenex, Aschaffenburg, Germany), at a flow rate of 0.25 mL/min. The mobile 
phase consisted of water with 0.1 % formic acid (A) and acetonitrile with 0.1 % formic acid (B). The 
following gradient was used: 0-1 min: 2.5 % B, 1-20 min: 2.5 % to 30 % B, 20-24 min: 30 %-97.5 % B, 
24-28 min: 97.5 % B, 28-29 min: 97.5 %-2.5 % B and 29-34 min: 2.5 % B. The injection volume was 
2.5 µL. 
 
For the analysis of blood and urine samples the following gradient was used: 0-1 min: 2.5 % B, 1-7 
min: 2.5 % to 97.5 % B, 7-11 min: 97.5 % B, 11-11.01 min: 97.5 %-2.5 % B, and 11.01-14 min: 2.5 % B 
for reequilibration. The flow rate was set at 0.35 mL/min. Chromatographic separation was 
performed on a Kinetex C8 column, 2.6 µm, 100 Å, 50 x 2.1 mm (Phenomenex, Aschaffenburg, 
Germany). The mass spectra were acquired in positive mode and Tof-MS and Tof-MS/MS scan 
modus. A volume of 2.5 µL of the processed, blood and urine sample was injected for analysis. 
 Quantification of 5-MeO-MiPT in authentic blood and urine samples using LC-MS/MS 
An HPLC System 1200 (Agilent, Waldbronn, Germany) coupled to a QTRAP 3200 hybrid mass 
spectrometer with Analyst 1.5.1 software (Sciex, Toronto, Canada) was used for the quantification of 5-
MeO-MiPT in authentic case samples. Following settings were applied: chromatographic separation 
was performed on a reversed phase Kinetex C8 column, 2.6 µm, 100 Å, 100 x 2.1 mm (Phenomenex, 
Aschaffenburg, Germany). The mobile phase consisted of water with 0.1 % formic acid (A) and 
acetonitrile with 0.1 % formic acid (B). The injection volume was 20 µL. The chromatographic 
gradient was used at a flow rate of 0.35 mL/min: 0-1 min: 2.5 % B, 1-10 min: 2.5 % to 30 % B, 10-12 
min: 30 %-97.5 % B, 12-14 min: 97.5 % B, 14-15 min: 97.5 %-2.5 % B and 15-20 min: 2.5 % B. MS data 
was acquired in positive ionization mode with an ion source voltage of 4500 V, a source temperature 
of 650 °C, curtain gas was set to 25 arbitrary units, gas 1 and 2 to 40 arbitrary units. Selected 
reaction monitoring (SRM) experiments were run using parameters presented in Table 1. 
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Evaluation of extraction efficiency, matrix effects and recovery of 5-MeO-MiPT in pHLM samples 
and authentic blood samples using LC-MS/MS 
Extraction efficiency, matrix effects, and recovery for phLM and blood samples were evaluated 
according to Matuszewski et al. [51] using three different sets of samples (n = 6, concentration for 
pHLM samples 100 µM, concentration for blood samples low and high QC level, 15 und 400 ng/mL). 
MDMB-d5 was used as an internal standard. Set A consisted of pHLM and blood samples which were 
spiked with the 5-MeO-MiPT reference standard prior to extraction. Set B samples were extracted 
blank samples spiked with a reference standard of 5-MeO-MiPT after extraction and set C consisted 
of neat 5-MeO-MiPT reference standard samples prepared in pure HPLC solvent. Measurements 
were performed on the LC-MS/MS as previously described for pHLM using a selected reaction 
monitoring (SRM) method with mass spectrometric parameters of 5-MeO-MiPT and MDMB-d5 as 
described in Table 1. Chromatographic conditions for pHLM samples were identical as for the LC-HR-
MS/MS analysis and chromatographic conditions for blood samples were the same as for the 
quantification of 5-MeO-MiPT. MS settings were the same as for the quantification of case samples. 
Calculations were based on the mean peak areas obtained for each set, using the following 
formulae: extraction efficiency = A/B x 100, matrix effect = B/C x 100 and recovery = A/C x 100.  
Matrix effects for the urine sample were assessed by comparison of the 5-MeO-MiPT concentration 
determined by the external seven-point calibration method and a two-point standard addition 
method. The authentic urine sample was diluted 1:10 (v/v) with blank urine and aliquots thereof 
were spiked with 300 ng/mL and 600 ng/mL of 5-MeO-MiPT reference standard, respectively. The 
unspiked sample and the two spiked samples were measured in triplicates using the previously 
described SRM method. The mean peak area was plotted against concentration and the resulting 
three-point calibration line was extrapolated to zero response (y = 0). The absolute value of the x-
intercept corresponds to the 5-MeO-MiPT concentration present in the tenfold diluted authentic 
urine sample [52]. 
Qualitative analysis of seized pills and powder samples 
FTIR-UATR 
A Fourier-transformation-infrared-spectrometer with a Universal-Attenuated-Total-Reflectance 
polarization accessory (FTIR-UATR) and Spectrum v2.00 software (Perkin Elmer, Schwerzenbach, 
Switzerland) was used for the identification of seized pills and powder. Scan range was from         
4000 cm-1 to 400 cm-1 with a resolution of 4 cm-1. Pills were homogenized for 30 seconds in a mortar 
and placed on the UATR for measurement. Powder samples were directly analyzed without any pre-
treatment.  
GC-MS  
A Clarus 500 Gas-Chromatograph coupled to a Clarus 560S single quadrupole mass spectrometer 
with Turbochrom software was used (Perkin Elmer, Schwerzenbach, Switzerland). Separation was 
performed on a capillary 5% phenyl-methyl-polysiloxane column (Perkin Elmer, Schwerzenbach, 
Switzerland). GC-Interface temperature was set to 280 °C, the source temperature to 250 °C and the 
electron multiplier voltage to 500 V. MS scan range was from 35-450 amu. GC temperature gradient 
was the following: 0-3 min: 80 °C, 3-10 min: 15 °C/min to 280 °C and held for 20 min at 280 °C 
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resulting in a total run time of 20 min. Injection volume was 0.5 µL (splitless) and the carrier gas was 
helium with a flow rate of 1 mL/min and a split flow of 30 mL/min. Samples were dissolved in 
methanol with a concentration of 0.05 mg/mL, ultrasonicated and filtered prior to analysis.  
NMR Spectroscopy 
NMR data of powder sample 2 dissolved in CDCl3 were acquired at room temperature using a Bruker 
Avance II spectrometer (Bruker BioSpin, Fällanden, Switzerland) operating at a resonance frequency 
of 400.13 and 100.62 MHz for 1H- and 13C-nuclei, respectively, and equipped with a 5 mm dual probe 
(BBI) for inverse detection with a z-gradient coil. The 1H and 13C NMR spectra were recorded using 
the standard zg30 and zgpg30 pulse program, respectively, from the Bruker pulse-program library. 
For the 1H NMR spectrum a total of 64 transients were collected into 65,536 data points over 
a spectral width of 25 ppm with an acquisition time of 3.29 s, a relaxation delay of 6 s and a 90°-
pulse width of 10 μs. For the 13C NMR spectrum 2048 transients were acquired over a spectral width 
of 270 ppm, a data size of 65’536 points, an acquisition time of 1.21 s, a relaxation delay of 1 s and a 
90°-pulse width of 9.5 μs. Acquisition and processing of both spectra was performed using the 
Bruker Topspin software version 3.5 and confirmed by calculated spectra (ACD/NMR Predictors 
software version 2016.1, Advanced Chemistry Development, Inc., Toronto, ON, Canada). 
The co-added free induction decays (FIDs) were exponentially weighted with a line broadening factor 
of 1.0 Hz, Fourier-transformed, and phase- and baseline-corrected. Chemical shifts δ are reported in 
parts per million (ppm) relative to tetramethylsilane (0.00 ppm).  
Results and Discussion 
The data obtained were compared to negative and blank samples in the case of pHLM and to blank 
value blood and urine samples from volunteers. The problem of checking for precursors of 
metabolites and/or endogenous substances was overcome by comparing potential metabolites 
found in the case samples to blank blood and blank urine samples.  
In total, nine different metabolites of the synthetic tryptamine 5-MeO-MiPT were detected and 
identified in the in vitro microsomal pHLM assay and in the authentic blood and urine samples by LC-
HR-MS/MS. Table 2 lists all detected and identified metabolites plus the parent drug along with the 
molecular formulae and monoisotopic masses. Table 2 also indicates whether the metabolites were 
detected in vitro, in blood or in urine. Figure 1 presents the postulated metabolic pathway of 5-MeO-
MiPT. Chromatograms of all three sample types are depicted in the supporting information Figures 
S1-S3. In all three sample types only phase I metabolites were detected. 5-Hydroxy-N-
isopropyltryptamine (5-MeO-NiPT, m/z 233.1576), 5-hydroxy-N-methyl-N-isopropyltryptamine (5-
OH-MiPT, m/z 233.1576), hydroxy-5-methoxy-N-methyl-N-isopropyltryptamine isomer 1 and 2 (OH-
5-MeO-MiPT, m/z 263.1754) and 5-methoxy-N-methyl-N-isopropyltryptamine-N-oxide (5-MeO-
MiPT-N-oxide, m/z 263.1754) had the highest L-HR-MS/MS signal intensities. The corresponding 
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Identification of metabolites  
The fragmentation of the parent compound (precursor ion [M+H]+ m/z 247.1805) yielded product 
ions of m/z 174.0918, m/z 131.0733, and m/z 86.0967 (Figure 2a). These product ions are formed by 
cleavage of the amine side-chain, simultaneous O-demethylation of the 5-methoxy substituent and 
β-cleavage releasing N-methyl-N-isopropyl-N-ethylamine and α-cleavage producing the iminium ion, 
respectively. Fragmentation of metabolites follows a similar pattern with O-demethylation, N-
dealkylation and α-cleavage as predominant fragmentation patterns of metabolites. Mass spectra of 
the parent compound and detected metabolites contained a product ion of m/z 115.0545, 
suggesting an intact indole core structure. This in turn indicates that biotransformation takes place 
either at the 5-methoxy group or the side-chain. A metabolite product ion of m/z 86.0967 suggests 
that the N,N-dialkylated amino group remained unaltered during biotransformation, whereas the 
presence of a product ion of m/z 72.0812 indicates that N-demethylation has occurred. When a 
product ion of m/z 174.0918 is found in the mass spectrum of a metabolite, then no 
biotransformation took place on the 3-ethyl-5-methoxy-1H-indole moiety. 
In vitro metabolism  
Seven distinctive phase I metabolites were detected in vitro using microsomal pHLM experiments 
(see detailed list in Table 3). The parent compound 5-MeO-MiPT was identified with the in-house 
Designer Drug Library (HR-MS/MS) and the reference spectrum of a 5-MeO-MiPT standard. The 
metabolic steps observed were N-demethylation, O-demethylation, demethylation and 
hydroxylation and N-oxide formation and hydroxylation of the parent compound and N-O-bis-
demethylation of the metabolite 5-OH-MiPT. The resulting metabolite 5-hydroxy-N-
isopropyltryptamine (5-OH-NiPT, m/z 218.1420) was only detected in vitro. Simultaneous 
demethylation and hydroxylation of the parent compound produced the metabolite bishydroxy-N-
methyl-N-isopropyltryptamine (Bishydroxy-MiPT, m/z 248.1525). The exact site of hydroxylation for 
the bishydroxy-MiPT metabolite could not be located. This metabolite was present in vitro and in 
vivo in urine.  
In vivo metabolism 
In blood four and in urine seven phase I metabolites were found (see detailed list in Table 4 and 5, 
respectively). The parent drug 5-MeO-MiPT was found in both, blood and urine. Hydroxylation of the 
parent compound formed two isomeric metabolites OH-5-MeO-MiPT. For these two isomers of OH-
5-MeO-MiPT the site of hydroxylation could be narrowed down to the indole ring. 5-MeO-MiPT-N-
oxide was formed by N-oxidation of the parent compound which is coherent with this metabolite 
eluting after the parent compound. N-oxides typically elute later on reversed-phase columns [53]. 
Loss of the N-methyl-N-isopropyl moiety by oxidative deamination and further oxidation of the 
intermediate aldehyde (5-MeO-indole-3-acetaldehyde, m/z 189.0790) to carboxylic acid led to the 
formation of the metabolite 5-MeO-indole-acetic acid (m/z 205.0793).  
Studies on 5-MeO-DiPT [54] showed a very similar phase I metabolic pathway for this synthetic 
tryptamine. The three main routes identified were also O-demethylation of the 5-methoxy group, 
hydroxylation of the aromatic ring and side-chain N-dealkylation. In contrast to the present study, 
they found that phase II metabolites were formed by sulfonation and glucuronidation of the mainly 
formed metabolites. Shima et al.[45] identified three different metabolites (5-OH-MiPT, 5-MeO-NiPT, 
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6-OH-5-MeO-MiPT) in blood and urine, each specimen from a different individual after intoxication 
with 5-MeO-MiPT. Additionally we were able to detect and identify 5-MeO-MiPT-N-oxide as in vivo 
metabolites in human blood specimen. Further analysis of the urine sample led to the identification 
of four additional in vivo metabolites (compared to the study presented by Shima et al [45]). Fabregat-
Safont et al. [46] recently reported on four different 5-MeO-MiPT metabolites in serum and urine 
samples of C57BLJ/6 male mice. Two phase I metabolites (5-OH-MiPT and 5-MeO-MiPT-N-oxide) and 
two phase II metabolites (glucuronides) were found. In comparison we were able to detect 
additional five phase I metabolites in human blood and urine but no phase II metabolites. The 
presence of two glucuronide metabolites in mice urine but absence of them in human urine is very 
likely due to interspecies differences- clearance of a free drug has been observed to be faster in 
smaller animals than in large species[55].  
General-unknown screening results  
Our routine GC-MS screening of the urine sample detected cocaine and its metabolites, 
cocaethylene, which is due to the combined consumption of cocaine and alcohol [56] and the cocaine 
adulterants levamisole, paracetamol, and phenacetin. Furthermore, chinine, nicotine and its 
metabolite cotinine and caffeine and its metabolites theophylline and theobromine as well as 
methylphenidate and ritalinic acid were found in the urine sample. The routine LC-HR-MS/MS 
screening method described earlier, detected in the urine sample cocaine and its metabolites, 
cocaethylene, methylphenidate and ritalinic acid and 5-MeO-MiPT. Additionally, methylphenidate 
and its metabolite ritalinic acid, with concentrations of 1.36 ng/mL and 64.1 ng/mL in blood and 671 
ng/mL and 2230 ng/mL in urine, respectively, were quantified. In blood the cocaine metabolites 
benzoylecgonine and ecgonine methylester were found with concentrations of 305 ng/mL and 21 
ng/mL and methylphenidate and ritalinic acid with concentrations of 2.6 ng/mL and 60 ng/mL, 
respectively. The absence of cocaine and the presence of methylphenidate in a subtherapeutic range 
[57] point towards an earlier consumption. Therefore the conations as well as the disoriented, 
agitated and aggressive state of the 32 year old man could be solely due to the consumption of 5-
MeO-MiPT.  
Evaluation of EAWAG-BBD Pathway Prediction System 
The software was a helpful tool in the identification of phase I metabolites. Unfortunately it is not 
able to predict phase II metabolites. Therefore, glucuronides and sulfates needed to be predicted by 
the authors. Furthermore the prediction system produces chemical structures and likelihoods of 
possible metabolites. In order to use predicted metabolites for the evaluation of data it is necessary 
to calculate the molecular formula and monoisotopic mass of possible metabolites. This means the 
predictions cannot be used without additional effort. Nevertheless, the software was able to predict 
six of the found nine metabolites.  
Quantification of 5-MeO-MiPT in whole blood and urine samples 
Quantification of 5-MeO-MiPT in the authentic blood and urine sample was performed using a 
seven-point calibration (R= 0.994 and 0.998 respectively). In the blood sample a 5-MeO-MiPT 
concentration of 160 ng/mL was determined. The authentic urine sample exceeded the calibration 
range and hence was diluted with blank urine (1:10 v/v) and reanalyzed with newly prepared 
calibration standards and QC samples. The concentration of 5-MeO-MiPT in urine was 3380 ng/mL.  
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Evaluation of extraction efficiency, matrix effects and recovery 
For pHLM samples extraction efficiency, matrix effects and recovery were determined at a 
concentration of 100 µM for both extraction methods (protein precipitation, liquid-liquid 
extraction). All values are presented in the supporting information in Table S1. Extraction efficiency, 
matrix effects and recovery were slightly higher for protein precipitation than for liquid-liquid 
extraction. Matrix effects were not significant for either extraction method. Furthermore, extraction 
efficiency, recovery and matrix effects were determined for the extraction of blood samples at 
concentrations of the QC1 (15 ng/mL) and QC3 (400 ng/mL) samples using the quantifier SRM 
transition for both analyte and ISTD. Results for the analyte were the following: extraction efficiency 
was 81 % and 86 %, matrix effects were 94 % and 91 % and recovery was 76 % and 78 % for QC1 and 
QC3, respectively. In comparison results for the ISTD were: extraction efficiency 72 % and 74 %, 
matrix effect 110 % and 103 %, and recovery 80 % and 77 % for QC1 and QC3, respectively. No 
significant matrix effects were observed. 
Matrix effects for the urine sample were determined by comparison of the external seven-point 
calibration method, used for the quantification of 5-MeO-MiPT in urine, and a two-point standard 
addition method. For the external calibration a 5-MeO-MiPT concentration of 3380 ng/mL was 
determined and with the two-point standard addition method a concentration of 3604 ng/mL. 
Hence no relevant matrix effects were observed.  
Qualitative analysis of seized pills and powder samples 
Four seized samples were analyzed using FTIR, GC-MS and LC-HR-MS/MS. The FTIR analysis results 
showed that the pills (sample 1) consisted of saccharose. Powder samples 2 and 3 were identified as 
5-MeO-MiPT by comparison with a reference standard (see supporting information Figure S5). The 
FTIR spectrum presented in Figure S5 displays sample 3 (purple, upper spectrum) in comparison with 
the reference material (5-MeO-MiPT·HCl, black, lower spectrum) with a correlation factor of 0.9848.  
The GC-MS results confirmed previous FTIR results using SWGDRUG MS Library Version 3.1 
(November 29, 2016). Further, powder sample 4 was identified as α-PVP, which is a scheduled 
synthetic cathinone [58]. The chromatogram of sample 2, 3 of and the 5-MeO-MiPT reference 
standard showed a single peak at a retention time of 15.15 min. The mass spectrometric 
fragmentation was characteristic for 5-MeO-MiPT (Figure S3), library search match was 89.6%. 
Finally, 5-MeO-MiPT with the sum formula C15H22N2O and a calculated [M+H]
+ of m/z 247.1805, was 
found at m/z 247.1805 in the HR-MS spectrum.  
NMR spectroscopy confirmed that the seized powder sample 2 was 5-MeO-MiPT hydrochloride. The 
1H NMR spectrum with assigned peaks is shown in Figure S7 and the 13C NMR spectrum in Figure S8 
(supporting information). Peak assignment was accomplished based on the observed chemical shift 
values, splitting patterns and integrated peak intensities and was confirmed by calculated chemical 
shift data (ACD/NMR Predictors software version 2016.1, Advanced Chemistry Development, Inc., 
Toronto, ON, Canada) as well as literature data [18]. Splitting of the 1H NMR signal of the N-methyl 
group into a doublet is most likely due to coupling with the N+H proton, as discussed for other amine 
hydrochloride salts [59-61]. Observed 1H resonance multiplicities and 1H-1H coupling constants, as well 
as a comparison between measured and calculated 1H and 13C chemical shift values are given in 
Table S2 (supporting information). 
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Conclusion 
In the present study, in total nine different metabolites of the synthetic tryptamine 5-MeO-MiPT 
could be identified, therefrom seven in vitro, and two additional in vivo. Results from human 
samples (in vivo) showed that in blood four different metabolites and in urine seven distinctive 
metabolites were present. The parent compound was detectable in blood and urine using LC-HR-
MS/MS and was quantified using LC-MS/MS. 5-MeO-MiPT concentrations were 160 ng/mL in blood 
and 3380 ng/mL in urine. The five most abundant metabolites were formed by demethylation and 
hydroxylation of the parent compound. For the development of new methods for the detection of 5-
MeO-MiPT consumption, the authors recommend 5-methoxy-N-isopropyltryptamine (5-MeO-NiPT), 
5-hydroxy-N-methyl-N-isopropyltryptamine (5-OH-MiPT), 5-methoxy-N-methyl-N-
isopropyltryptamine-N-oxide (5-MeO-MiPT-N-oxide) and hydroxy-5-methoxy-N-methyl-N-
isopropyltryptamine (OH-5-MeO-MiPT) as biomarkers, as they have been present in both blood and 
urine samples.  
Future Perspective 
Performing in vitro experiments generating phase II metabolites and further kinetic and inhibitory in 
vitro studies to determine the responsible cytochrome P450 (CYP) enzymes appears desirable at this 
point. In addition, other approaches for generating metabolites such as fungal in vitro assays could 
be cross validated using gained results.  
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Tables 
Tables 1: Optimized MS/MS parameters for selected reaction monitoring (SRM) experiments.  
 Q1 [Da] Q3 [Da] DP [V] EP [V] CEP [eV] CE [V] CXP [V] 
Qualifier 247 174.1 37 5 16 27 3 
Quantifier 247 159.2 37 5 16 38 3 
ISTD 213 136,1 40 4 16 20 4 
Q1 m/z of the precursor ion 
Q3 m/z of the fragment ion 
DP declustering potential 
EP entrance potential 
CE collision energy 




Table 2: Identified in vivo and in vitro metabolites of 5-MeO-MiPT in the order of their monoisotopic 
mass. The presence of a metabolite in vitro, in vivo (blood) or in vivo (urine) is denoted with +, the 
absence with a -.  
Compound Name Formula Mass [Da] In vitro  
(pHLM) 
In vivo  
(urine) 
In vivo  
(blood) 
5-MeO-indole-3-acetaldehyde C11H11NO2 189.0790 - + - 
5-MeO-indole-acetic-acid C11H11NO3 205.0739 - + - 
5-OH-NiPT C13H18N2O 218.1419 + - - 
5-MeO-NiPT C14H20N2O 232.1576 + + + 
5-OH-MiPT C14H20N2O 232.1576 + + + 
5-MeO-MiPT (parent drug) C15H22N2O 246.1732 + + + 
Bishydroxy-MiPT C14H20N2O2 248.1525 + + - 
OH-5-MeO-MiPT isomer 1 C15H22N2O2 262.1681 + + + 
5-MeO-MiPT-N-oxide C15H22N2O2 262.1681 + + + 
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Table 3: 5-MeO-MiPT and identified in vitro metabolites of 5-MeO-MiPT after 120 minutes 
incubation with pHLM in the order of the protonated molecule [M+H]+ [m/z]. A 34 minute 
chromatographic method has been applied. The three most abundant fragments are listed with their 
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Table 4: 5-MeO-MiPT and identified in vivo metabolites of 5-MeO-MiPT in urine, ordered according 
to the protonated molecule [M+H]+ [m/z]. A 14 minute chromatographic method has been applied. 
The last four listed substances in grey are due to the consumption of cocaine and methylphenidate 
and are listed for completeness. For 5-MeO-MiPT metabolites the three most abundant fragments 





























































































































OH-5-MeO- Hydroxylatio C15H22 263.175 263.1754 -0.1 3.04 2529 190.08
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Table 5: 5-MeO-MiPT and identified in vivo metabolites of 5-MeO-MiPT in blood, ordered according 
the protonated molecule [M+H]+ (m/z). A 14 minute chromatographic method has been applied. The 
three most abundant fragments are listed with their relative percentage to the base peak as an 
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Figure 1 Metabolic pathway of 5-MeO-MiPT, metabolites labelled in black (1) were found in all three 
sample types, red (2) only in vitro, green (3) in vitro- urine and blue (4) in both in vitro and in vivo- 
urine.  
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Figure 2 Product ion mass spectra of 5-MeO-MiPT and two of its metabolites 5-OH-MiPT and 5-MeO-
NiPT found in vitro by IDA experiments. Fragmentation was selected for the ten most abundant 
precursor ions with CE of 35 eV with a CES of ± 15 eV. 
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Figure 3 Product ion mass spectra of three metabolites with m/z 263.1754, 5-MeO-MiPT-N-Oxide 
and OH-5-MeO-MiPT isomer 1 and 2. All three metabolites were found in vitro and in vivo in blood 
but only 5-MeO-MiPT-N-Oxide and one isomer of OH-5-MeO-MiPT were found in vivo in urine. 
Fragmentation was selected for the ten most abundant precursor ions with CE of 35 eV with a CES of 
± 15 eV. 
 
 
